From The School of Biomedical Sciences Wiki
Revision as of 09:25, 25 October 2018 by 170404642 (Talk | contribs)
Jump to: navigation, search

CRISPR is the abbreviation of clustered regularly interspaced short palindromic repeats, a mediated defense mechanism adopted by prokaryotes.The widely applied CRISPR technology is the Crispr/Cas system for gene sequence editions by transferring Cas9 protein family encoded gene into cells and potentially simplifies the procedure of cutting DNA at a desired location[1]. Cas9 was first used for targeted genome editing in prokaryotes by Prof. Emmanuelle Charpentier & Prof. Jennifer Doudna (2012) and later adapted for use in eukaryotes by Prof. Feng Zhang (2013).

There are three CRISPR systems, one of which has been adapted for eukaryotes. This is the Type II CRISPR system, which involves Cas9 protein, and it consists of three stages summarised briefly below:

  1. Acquisition/Adaptation: Cas 1 and Cas2 proteins will bind to the foreign DNA and then cut it forming protospacers. This will be incorporated into the CRISPR strand Locus, inserted with a ligase and then extending either side to form the repeat patterns to distinguish between spacers. At this stage, we have pre-crRNA
  2. Processing/Expression: Here we have a helper RNA called the tracerRNA which will bind to the repeat patterns between spaces forming a duplex. This duplex will act asa target site for the Cas proteins as to where to cut. Here Cas 9 and RNase III are used. This is thesystem that has been hijacked to be used in eukaryotic systems.
  3. Interference, where the mature crRNA:tracrRNA complex directs cas9 to the target DNA via base pairing between the spacer on the crRNA and the protospacer on the target DNA next to the PAM (Protospacer Adjacent Motif, is the sequence 5'-NGG-3' where "N" is any base). Finally, Cas9 mediates cleavage of target DNA to create a double-stranded break within the protospacer.

In the event the molecule of choice for the invading genetic code is RNA, Cas 2 acts first by converting RNA into DNA through the use of an endoribonuclease.

The DNA repairs this double stranded break (DSB) by either non-homologous end joining (NHEJ) or homology directed repair (HDR). CRISPR uses NHEJ to knockout a gene from an organism, whereas HDR is used to insert a gene into an organism's genome. More differences between the two are highlighted here[2].

The CRISPR technology is now being used in genome editing, and in particular to fight disease. For example, specific gRNA molecules are being specifically designed alongside Cas9 to target antibiotic resistance genes in prokaryotes. CRISPR technology is also being adapted to treat genetic diseases such as Duchenne Muscular Dystrophy (DMD), which causes a lack in dystrophin which helps to protect muscles from injury, through in vivo genome editing. Caused by a mutation inactivating the dystrophin gene on the X chromosome, the injection of viral vectors coding for CRISPR/Cas9 is seeing early success in treating mice[3]. Alongside this, labs are trying to modify mosquitos to release into the wild in order to eradicate malaria, however, there are some ethical concerns stipulating this e.g. "designer babies" using genome editing. As a pioneer of the CRISPR/Cas9 technology, Prof. Jennifer Doudna responsibly called for a "global pause" in any clinical application of the CRISPR technology in human embryos to give time to consider the implications of doing so, just as scientists did in the 70s to consider the use of molecular cloning. However, she did say during a TED talk on CRISPR in 2015 that even though genome-engineered humans aren't with us yet, "this is no longer science fiction" and that "in the end, this technology will be used for human genome engineering".


Figure 1 CRISPR as a genome editing tool[4]


  1. Ledford H (3 June 2015). "CRISPR, the disruptor". News Feature. Nature 522 (7554).
  2. Bollen Y, Post J, Koo B, Snippert H: How to create state-of-the-art genetic model systems: strategies for optimal CRISPR-mediated genome editing. Nucleic Acids Research (2018) 46:6435-6454.
  3. Nelson CE, Hakin CH, Ousterout DG, Thakore PI, Moreb EB et al. In vivo genome editing improves muscle function in mouse model of Duchenne muscular dystrophy. Science 2016; 351(6271)pp403-407:
  4. Alberts et al (2015). Molecular Biology of the Cell. 6th ed. New York: Garland Science. 497
Personal tools